RHYTHM PHARMACEUTICALS, INC. 4

President and CEO David P. Meeker of Rhythm Pharmaceuticals (RYTM) exercised 50,000 stock options at $6.05 and sold 48,000 common shares around $102–$105 on September 14, 2026, retaining 239,258 shares afterward.

On September 14, 2026, Rhythm Pharmaceuticals President and CEO David P. Meeker exercised 50,000 stock options at $6.05 per share, acquiring 50,000 shares of common stock, and on the same day sold a total of 48,000 shares in multiple open-market transactions at weighted average prices between approximately $101.75 and $105.19 per share under a pre-arranged Rule 10b5-1 trading plan. The option exercise had an intrinsic value of roughly $4.8 million, while the related stock sales generated proceeds of about $4.9–$5.0 million, leaving Meeker with direct ownership of 239,258 shares after the transactions, including 242 shares acquired via the company’s employee stock purchase plan. The options exercised were originally granted on February 8, 2017 and had fully vested in three annual installments beginning January 6, 2017, indicating this is largely a liquidity/monetization event of long-held awards rather than a change in his compensation structure.

Filing Facts

CIK

1649904

Ticker

RYTM

Form

4

Source Type

fda

Accession

0001649904-26-000026

Alert Tier

6